MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-53M

42M

Ventes

-65M

665M

P/E

Moyenne du Secteur

39.967

40.527

BPA

1.01

Rendement du dividende

0.29

Marge bénéficiaire

6.268

Employés

11,000

EBITDA

-50M

173M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+15.71% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.29%

2.40%

Prochains Résultats

28 juil. 2025

Date du Prochain Dividende

8 août 2025

Date du Prochain Détachement de Dividende

18 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.6B

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

31%

69%

71 / 375 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 juil. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Received All Required Authorizations

4 juil. 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Agreement Was Announced on Dec. 19

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 juil. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 juil. 2025, 14:30 UTC

Acquisitions, Fusions, Rachats

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 juil. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 juil. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 juil. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 juil. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 juil. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

15.71% hausse

Prévisions sur 12 Mois

Moyen 117.23 USD  15.71%

Haut 135 USD

Bas 100 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

9

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

71 / 375Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.